Showing results (21-30 of 49) with videos related to
Sort By:
Pageof 5
American Journal of Surgery|December 13, 2006
Size of sentinel node metastases predicts other nodal disease and survival in malignant melanomaNathan W Pearlman, Martin D McCarter, Matthew Frank, et al.American Journal of Surgery|February 1, 2016
Association of sentinel lymph node diameter with melanoma metastasisJustin Merkow, Alessandro Paniccia, Edward Jones, et al.Investigational New Drugs|January 20, 2010
A phase I dose-escalation, safety and pharmacokinetic study of the 2-methoxyestradiol analog ENMD-1198 administered orally to patients with advanced cancerQing Zhou, Daniel Gustafson, Sujatha Nallapareddy, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2005
Serial monitoring of circulating melanoma cells during neoadjuvant biochemotherapy for stage III melanoma: outcome prediction in a multicenter trialKazuo Koyanagi, Steven J O'Day, Rene Gonzalez, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 21, 2006
Microphthalmia transcription factor as a molecular marker for circulating tumor cell detection in blood of melanoma patientsKazuo Koyanagi, Steven J O'Day, Rene Gonzalez, et al.The Lancet. Oncology|February 26, 2018
Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trialMichele Maio, Karl Lewis, Lev Demidov, et al.Cancers|August 23, 2020
A Phase II Study of Glembatumumab Vedotin for Metastatic Uveal MelanomaMerve Hasanov, Matthew J Rioth, Kari Kendra, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 18, 2022
ARRY-382 in Combination with Pembrolizumab in Patients with Advanced Solid Tumors: Results from a Phase 1b/2 StudyMelissa Johnson, Arkadiusz Z Dudek, Ammar Sukari, et al.European Journal of Cancer (Oxford, England : 1990)|November 10, 2019
Health-related quality of life in patients with fully resected BRAFV600 mutation-positive melanoma receiving adjuvant vemurafenibDirk Schadendorf, Anna Maria Di Giacomo, Lev Demidov, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|July 31, 2014
Retrospective analysis of the safety and efficacy of high-dose interleukin-2 after prior tyrosine kinase inhibitor therapy in patients with advanced renal cell carcinomaElaine T Lam, Michael K K Wong, Neeraj Agarwal, et al.Pageof 5